| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Cereblon
CRBN (cereblon), an E3 ubiquitin ligase. |
|---|---|
| ln Vitro |
This conjugate binds to cereblon via its lenalidomide moiety, recruiting the E3 ubiquitin ligase complex for targeted protein degradation when the terminal carboxylic acid or the acetylene group is used to attach a target protein ligand.
|
| ln Vivo |
No specific in vivo activity has been reported for this conjugate alone; however, a related STAT3 PROTAC synthesized using similar conjugates achieved complete tumor regression in mouse models.
|
| Enzyme Assay |
N/A; as an E3 ligase ligand-linker conjugate, its cereblon-binding affinity is typically characterized using biophysical methods. The acetylene group enables copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions.
|
| Cell Assay |
N/A; this conjugate alone is not tested in cell-based assays but is incorporated into complete PROTACs. The related STAT3 PROTAC has been shown to degrade STAT3 and inhibit tumor cell proliferation in vitro.
|
| Animal Protocol |
N/A; no animal studies are performed with the ligand-linker conjugate alone. A STAT3 PROTAC developed from a similar lenalidomide-based conjugate demonstrated complete tumor regression in vivo.
|
| ADME/Pharmacokinetics |
This compound has a molecular weight of 382.41 and is typically stored as a powder at -20degC for up to 3 years or in solvent at -80degC for up to 6 months. The combination of acetylene and carboxylic acid provides versatile conjugation options.
|
| Toxicity/Toxicokinetics |
This product is for laboratory research use only and is not for human therapeutic or clinical applications. Standard safe handling practices for chemical reagents and click chemistry precursors should be observed.
|
| References | |
| Additional Infomation |
The acetylene group supports click-chemistry applications, and the COOH moiety provides coupling versatility. This compound has been studied for applications in treating hematologic malignancies, particularly multiple myeloma.
|
| Molecular Formula |
C21H22N2O5
|
|---|---|
| Molecular Weight |
382.4098
|
| Exact Mass |
382.152
|
| CAS # |
2429878-72-6
|
| PubChem CID |
139600323
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
1.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
28
|
| Complexity |
719
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CC(=O)NC(=O)C1N2CC3=C(C=CC=C3C2=O)C#CCCCCCC(=O)O
|
| InChi Key |
UYYFKFKQSNARRT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H22N2O5/c24-18-12-11-17(20(27)22-18)23-13-16-14(8-6-9-15(16)21(23)28)7-4-2-1-3-5-10-19(25)26/h6,8-9,17H,1-3,5,10-13H2,(H,25,26)(H,22,24,27)
|
| Chemical Name |
8-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]oct-7-ynoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~115 mg/mL (~300.72 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 5 mg/mL (13.07 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (13.07 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6150 mL | 13.0750 mL | 26.1499 mL | |
| 5 mM | 0.5230 mL | 2.6150 mL | 5.2300 mL | |
| 10 mM | 0.2615 mL | 1.3075 mL | 2.6150 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
